Toshiba America Medical Systems unveiled a new ultrasound system at this month’s American Heart Association meeting in Atlanta. Cleared by the Food and Drug Administration, PowerVision 8000 is a 512-channel unit for cardiology configured for a range
Toshiba America Medical Systems unveiled a new ultrasound system at this months American Heart Association meeting in Atlanta. Cleared by the Food and Drug Administration, PowerVision 8000 is a 512-channel unit for cardiology configured for a range of clinical applications and calculation packages. Twelve transducers are available with the device, and users may purchase additional transducers to expand the systems applications.
PowerVision 8000 features Toshibas work-in-progress PowerView package, a digital information management system that supports all DICOM service classes; integrated 3-D and stress echo applications software; live digital streaming for telemedicine; and a quantitative analysis package. PowerView can be used to send still frame and dynamic images to review stations or printers, access worklist interfaces to the HIS/RIS system, and retrieve exams from archives.
PowerVision 8000 has a dynamic range of 175 dB. The unit supports Toshibas Flash Echo Imaging technology and color harmonics package, which allows clinicians to quantify blood flow and perfusion; and Automatic Cardiac Output, which measures cardiac output and stroke volume based on color Doppler principles. PowerVision also supports Quad Signal Processing, which improves the systems frame rate and color imaging, and True Triplex Imaging, which provides for real-time gray-scale, color, and Doppler imaging of up to 20 frames per second.
In other Toshiba ultrasound news, the Tustin, CA, company named Scott Yarde to the post of director, ultrasound marketing. Yarde joins Toshiba from Philips Medical Systems, where he served for seven years in various positions, including Southwest regional sales manager, Western zone MRI sales manager, and MRI product sales manager.
Can Ultrasound-Based Radiomics Enhance Differentiation of HER2 Breast Cancer?
March 11th 2025Multicenter research revealed that a combined model of clinical factors and ultrasound-based radiomics exhibited greater than a 23 percent higher per patient-level accuracy rate for identifying HER2 breast cancer than a clinical model.